AbbVie
2Q Revenues: $8.3 billion (+19%)
2Q Earnings: $2.0 billion (+4%)
YTD Revenues: $10.5 billion (+25%)
YTD Earnings: $4.8 billion (+31%)
Comments: HUMIRA sales increased 10% to $5.2 billion in the quarter. IMBRUVICA sales were $850 million, up 36%. Global HCV revenues were $973 million, up more than 100%. Creon sales were up 11% to $219 million. Lupron sales were $223 million, up 6%. Synthroid sales were flat at $193 million. AndroGel sales declined 17% to $128 million. Duodopa sales were $108 million, up 33%. Sevoflurane sales were up 8% to $113 million. Kaletra sales were down 18% to $91 million.